Novo Holdings, which controls obesity drugmaker Novo Nordisk, is sharpening its focus on India, targeting single-specialty hospitals and contract drugmakers to tap high-growth healthcare segments, according to a senior company executive.

Patients in the world’s most populous nation are increasingly preferring specialised amenities, which some analysts and industry insiders say will form the bedrock of demand in the Indian healthcare market. The sector is also booming with increasing private and foreign investments.

Novo Holdings, which had 142 billion euros ($165.60 billion) in assets under management by 2024-end, is in talks with several Indian companies, Amit Kakar, managing partner and head of Asia, told Reuters in an interview this week.

The life sciences investment powerhouse tha

See Full Page